2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2806 Predictors of kidney transplant waitlist approval in plasma cell disorders: A multicenter cohort study

Emelia Farnam, N/A, Krishna Chaitanya Allam, BMsc2, Gaddiel Ahmed, N/A3, Rosemary Attieh, MD4, Jalal Dildar, MD5, Zain El-amir, MD6, Christopher Blosser, MD7, Erica Campagnaro, MD8, Sami Elrazky, N/A9, Prakash Gudsoorkar, MD10, Hani Hassoun, MD11, Heather J. Landau, MD12, Matthew J. Pianko, MD13, Divya Ravi, N/A14, Allison Webber, MD15, Naoka Murakami, MD16, Sabine Karam, MD17
1 University of Michigan, Ann Arbor, Michigan, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 Ponce Health Sciences University SOM, Puerto Rico, Puerto Rico, United States
4 Mayo Clinic, Jacksonville, United States
5 Mayo Clinic, Jacksonville, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Washington, Seattle, Washington, United States
8 University of Michigan, Ann Arbor, Michigan, United States
9 University of Washington, Seattle, Washington, United States
10 University of Cincinnati, Cincinnati, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 University of Michigan, Ann Arbor, Michigan, United States
14 University of California at San Francisco, San Francisco, California, United States
15 University of California at San Francisco, San Francisco, California, United States
16 Washington University, Saint-Louis, United States
17 University of Minnesota, Minneapolis, Minnesota, United States

BACKGROUND

Kidney transplantation (KTx) is increasingly pursued for patients with plasma cell disorders (PCD) and end-stage kidney disease. Yet, predictors of waitlist approval, including social determinants, remain undefined. No multicenter data exist on referral outcomes among PCD patients.

METHODS

This retrospective multicenter cohort study, evaluated 172 adults with PCD (multiple myeloma [MM], AL amyloidosis, or monoclonal gammopathy of renal significance [MGRS]) referred for KTx evaluation across 6 US academic centers between 2014 and 2025. The primary outcome was waitlist approval (active or inactive listing) versus non-approval (denial, deferral, withdrawal, or death during evaluation). A modified Charlson comorbidity index (mCCI) was derived from a 16-item checklist, omitting the renal-disease component (constant across this cohort) and the primary PCD diagnosis. Systematic predictor selection identified race, education level, mCCI, referring physician practice type, and deep hematologic response (≥VGPR at referral). These predictors were tested using cluster-robust logistic regression with bootstrap-corrected inference (1,000 resamples). Sensitivity analyses included Firth penalized regression, multiple imputations (m = 50), mixed-effects and leave-one-center-out models, and multiplicity correction.

RESULTS

The cohort comprised 92 MM (53.5%), 33 AL amyloidosis (19.2%), and 32 MGRS (18.6%) patients; median age was 58 years, 44.8% were female, and 13.2% were of African descent. Of 134 patients with completed evaluations, 84 (62.7%) were approved, and 50 (37.3%) were not. Leading denial reasons were comorbidities/contraindications (38.5%), frailty (25.6%), and active disease (20.5%).

The mCCI was the strongest predictor of listing outcome: each unit increase was associated with lower approval odds (bootstrap-corrected OR 0.54, 95% CI 0.29–0.92), and it was the only predictor significant under both naive complete-case (OR 0.54, 95% CI 0.41–0.73; P < 0.001) and selection-corrected estimation. This finding held across all sensitivity frameworks (OR range 0.38–0.64; all P ≤ 0.026). Among individual comorbidities, cerebrovascular disease was the only item significantly associated with non-approval (16.0% vs. 2.4%; P = 0.006).

Referral by a university practice was associated with higher approval odds (OR 2.95, 95% CI 1.22 -- 7.14; P = 0.016; adjusted P = 0.033), though it appeared in only 53.5% of bootstrap resamples, indicating moderate stability. Higher education showed a similar direction (OR 2.08, 95% CI 1.02–4.22; P = 0.044) but lost significance after bootstrap correction (OR 2.29, 95% CI 0.75–7.20). Time to first evaluation decision varied markedly by center (median 3 to 235 days; P = 0.002) but not by race (P = 0.65).

African-descent race was associated with non-approval in unadjusted analysis (OR 0.42, 95% CI 0.17–1.01; P = 0.054) but not after adjustment (bootstrap-corrected OR 0.55, 95% CI 0.12–2.73). Safety-net insurance (Medicaid, uninsured, or unknown coverage) was more prevalent among African-descent patients (22.7% vs. 4.0%; OR 6.92, 95% CI 1.50 -- 30.6; P = 0.006), though it was not itself predictive of listing outcome. Comorbidity burden and hematologic response at referral together mediated approximately 40% of the race–listing association on the linear probability scale, suggesting these as modifiable contributors to the observed disparity.

CONCLUSIONS

In this largest multicenter study of KTx listing outcomes in PCD, comorbidity burden was the dominant predictor of waitlist non-approval, with cerebrovascular disease uniquely discriminating at the individual-comorbidity level. Referral by a university practice setting was independently associated with better approval rate, and evaluation timelines varied widely across centers, identifying structural targets for equitable access. Although the race–listing association was not independently significant, African-descent patients carried higher comorbidity burden and disproportionate safety-net insurance coverage, suggesting that earlier comorbidity optimization and insurance navigation, interventions actionable by both hematologists and nephrologists before transplant referral, may help narrow this disparity.

Sabine Karam, MD: No relevant conflicts of interest to declare.